🏛️ Verified NIH Record • Updated 2026-04-30
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics (NCT06109441)
Phase 2a, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of ALTB-268 in Subjects With Moderately to Severely Active Ulcerative Colitis Refractory to Biologic Therapy
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: AltruBio Inc.
🩺 Plain-English Summary (8th-Grade Level)
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase and a LTE (Long Term Extension)
Who can join: Review the eligibility criteria below.
Location: San Diego Gastroenterology — San Diego, California
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- San Diego Gastroenterology — San Diego, California
- Rocky Mountain Gastroenterology — Littleton, Colorado
- Gastro Health Research — Miami, Florida
- Digestive and Liver Center of Florida, LLC — Orlando, Florida
- Alliance Clinical Research of Tampa, LLC. — Tampa, Florida
- Gastro Health Partners Southern Indiana — New Albany, Indiana
- Gastro Health Partners Louisville — Louisville, Kentucky
- Louisiana Research Center, LLC. — Shreveport, Louisiana
- Gastroenterology Associates of North Mississippi — Oxford, Mississippi
- New York Presbyterian Hospital - Weill Cornell Medical Colllege — New York, New York
- Gastroenterology Group of Rochester — Rochester, New York
- Digestive Disease Medicine of Central New York — Utica, New York
- Dayton Gastroenterology, LLC — Beavercreek, Ohio
- Gastro Health Ohio — Liberty Township, Ohio
- Frontier Clinical Research, LLC — Uniontown, Pennsylvania
- Gastroenterology Associates, P.A. — Greenville, South Carolina
- DHAT / GI Aliance — Garland, Texas
- Caprock Gastro Reasearch — Lubbock, Texas
- GI Alliance — Mansfield, Texas
- Southern Star Research Institute LLC — San Antonio, Texas
- Tyler Research Institute — Tyler, Texas
- GI Alliance — Webster, Texas
- Wisconsin Center for Advanced Research — Milwaukee, Wisconsin
- Wellness Clinical Research, LLC — Vega Baja,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ulcerative Colitis
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) — Dothan, Alabama
- Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis — San Diego, California
- A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants — Eden Prairie, Minnesota
- CP101 for the Treatment of Ulcerative Colitis — Boston, Massachusetts
- A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis — Los Angeles, California
- Angiographic Delivery of AD-MSC for Ulcerative Colitis — Rochester, Minnesota
Explore by condition: All Ulcerative Colitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.